Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial-Reference-Cited by-同舟云学术

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Published:2021-02-24 Issue:7 Volume:17 Page:2107-2116
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Park Juliana¹,Archuleta Sophia²³,Oh May-Lin Helen⁴,Shek Lynette Pei-Chi⁵^ORCID,Wang Hao⁶,Bonaparte Matthew⁷,Frago Carina¹,Bouckenooghe Alain¹,Jantet-Blaudez Frederique⁸^ORCID,Begue Sarah⁸,Gimenez-Fourage Sophie⁸,Pagnon Anke⁸^ORCID

Affiliation:

1. Global Clinical Sciences, Sanofi Pasteur, Singapore, Singapore

2. Division of Infectious Diseases, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore

3. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

4. Department of Medicine, Changi General Hospital, Singapore, Singapore

5. Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

6. Biostatistics, Sanofi, Beijing, China

7. Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA, USA

8. Research and External Innovation Department, Sanofi Pasteur, Marcy l’Etoile, France

Funder

Sanofi Pasteur

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1861875

Reference22 articles.

1. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

2. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

3. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

4. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccines;Side Effects of Drugs Annual;2022